

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number
WO 02/00880 A1

- (51) International Patent Classification⁷: C12N 15/31, 1/19, 15/62, C12P 1/02, C07K 14/395
- (21) International Application Number: PCT/GB01/03079
- (22) International Filing Date: 29 June 2001 (29.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0002460-4 29 June 2000 (29.06.2000) SE
0004241-6 17 November 2000 (17.11.2000) SE
- (71) Applicant (*for all designated States except US*): **GOTHIA YEAST SOLUTIONS AB** [SE/SE]; Pionvägen 8, S-434 45 Kungsbacka (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BILL, Roslyn** [GB/SE]; Danska vägen 15, S-463 71 Lödöse (SE). **BOLES, Eckhard** [DE/DE]; Roentgenweg 5, 40591 Dusseldorf (DE). **GUSTAFSSON, Lena** [SE/SE]; Vit-mossegatan 12, S-431 69 Mölndal (SE). **HOHMANN, Stefan** [DE/SE]; Norra Häcksöbäcksvägen 46, S-443 32 Lerum (SE). **LARSSON, Christer** [SE/SE]; Kikåsgränden 23, S-431 64 Mölndal (SE). **OTTERSTEDT, Karin** [SE/SE]; Sterlingsgatan 2A, S-414 81 Göteborg (SE).
- (74) Agents: **JONES, Elizabeth, Louise et al.**; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: RECOMBINANT SACCHAROMYCES CEREVISIAE EXPRESSING CHIMERIC GLUCOSE TRANSPORTERS

(57) Abstract: The present invention provides a modified *Saccharomyces* yeast which produces significantly lower levels of ethanol than wild-type yeast under aerobic conditions and saccharide concentrations of 2 % glucose, and which exhibits a growth rate of at least 30 % of the wild-type yeast, preferably containing a chimeric construct of at least 2 saccharide transporters, nucleic acid molecules encoding the chimeras and polypeptides encoded by such sequences, and methods of using the modified yeast for preparing products in the yeast.

WO 02/00880 A1

RECOMBINANT SACCHAROMYCES CEREVISIAE EXPRESSING CHIMERIC GLUCOSE TRANSPORTERS

5 The present invention relates to a yeast having modified saccharide, particularly hexose, transporting properties and its use.

10 The purpose of the invention is to obtain a yeast having modified saccharide, particularly hexose transporting properties while simultaneously avoiding production of alcohol, in particular ethanol under aerobic conditions and high saccharide, particularly hexose concentrations.

15 Yeast glycolysis, the pathway which converts sugar into pyruvate, has a massive capacity as has been documented by the fact that 50-70% of the yeast's cellular protein consists of glycolytic enzymes. Not surprisingly, this pathway is controlled in a very complex way and by different partially redundant mechanisms (Fraenkel, 1982, Carbohydrate metabolism, p. 1-37, in "The molecular biology of the yeast *Saccharomyces cerevisiae*: Metabolism and gene expression" Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; Gancedo and Serrano, 1989, Energy-yielding metabolism, p. 205-259, in "The Yeasts", Rose and Harrison (Eds.), Second ed, vol. 3. Academic Press; 25 Zimmermann and Entian, 1997, Yeast sugar metabolism, in "Biochemistry, genetics, biotechnology and applications.", Technomic Publishing Co., Lancaster PA). Some of these seem to be shared with glycolytic pathways from other organisms up to humans and higher plants, but 30 others appear to be unique to yeast.

35 Regulation of yeast glycolysis occurs via allosteric control of key enzymes in the pathway such as phosphofructokinase (PFK) and pyruvate kinase (Blazquez et al., 1993, FEBS Lett., 329, p51-54; Boles et al., 1996, Mol. Microbiol., 20, p65-76; Campbell-Burk and Shulman, 1987, Ann. Rev. Microbiol., 41, p595-616;

- 2 -

Davies and Brindle, 1992, Biochemistry, 31, p4729-4735; Gancedo and Serrano, 1989, supra; Heinisch et al., 1996, J. Biol. Chem., 271, p15928-15933). For a long time PFK was considered to be the (single) rate-limiting step in glycolysis. The development of metabolic control analysis theory has shown this to be an oversimplification (Fell, 1997, in "Understanding the Control of Metabolism", Portland Press, London and Miami).

10 A control mechanism which is probably specific to yeast but of central importance, operates at the level of hexokinase and involves trehalose metabolism (Thevelein and Hohmann, 1995, Trends Biochem. Sci., 20, p3-10). Inactivation of trehalose-6-phosphate synthase
15 causes an absence of trehalose accumulation, but also a growth defect, specifically when grown on glucose (González et al., 1992, Yeast, 8, p183-192; Van Aelst et al., 1993, Mol. Microbiol., 8, p927-943). The
20 expression of heterologous trehalose-6-phosphate synthase in a mutant of *S. cerevisiae* lacking the same enzyme restored trehalose-6-phosphate levels as well as growth on glucose and glucose influx, at least partially (Bonini et al., 2000, Biochemical Journal, 15, p261-268).

25 Also other metabolites and/or co-metabolites such as ATP, ADP, NAD⁺ and Pi, may be involved at different levels such as allosteric control and the so-called "thermodynamic control" (alternatively "concentration" or "metabolite control") (Gancedo and Serrano, 1989,
30 supra). A strong "negative" correlation between the ATP content and glycolytic flux has been found, which points at an allosteric control of flux. In a recent study it has been shown that the target for ATP inhibition in permeabilised cells was mainly at the level of
35 phosphofructokinase and pyruvate kinase (Larsson et al., 2000, Yeast, 16, p797-809).

Altering expression of genes encoding glycolytic

- 3 -

enzymes and proteolysis of glycolytic enzymes are other levels of regulation and control, which is far from understood when considering glycolytic control (Hohmann, 1997, p 187-211, in "Yeast sugar metabolism.

5 Biochemistry, genetics, biotechnology and applications", Zimmermann and Entian (Eds.), Technomic Publishing Co. Inc., Lancaster, PA; Larsson et al., 1997, J. Bacteriol., 179, p7243-7250).

10 The yeast *S. cerevisiae* has a remarkable metabolic flexibility and it is one of the few yeasts which is able to grow fermentatively under strict anaerobic conditions (Visser et al., 1990, Appl. Environ. Microbiol., 56(12), p3785-3792). During aerobic conditions and with simultaneously relatively high
15 external glucose concentrations, the Crabtree effect is exerted, which results in ethanol production also during aerobic growth on fermentable sugars (Fraenkel, 1982, supra; Gancedo and Serrano, 1989, supra). A number of causes of the Crabtree effect have been put forward.
20 Firstly, it has been suggested that increased extracellular (or intracellular) levels of glucose cause repression of the activity of key elements of the respiratory pathway leading instead to processing via the fermentation pathway. Alternative explanations
25 suggest that the effect may simply occur through overload of the glycolytic pathway leading to a shunt of carbon sources to fermentative processes.

As mentioned above, glucose repression (= (carbon) catabolite repression) may be part of the explanation
30 for aerobic ethanol production during growth on fermentable sugars (Fraenkel, 1982, supra; Gancedo and Serrano, 1989, supra; Gancedo, 1992, Eur. J. Biochem., 206, p297-313). The primary effect of glucose repression is that glucose and fructose are the
35 preferred carbon sources if a mixture of different sources is available. There is a whole series of genes involved in glucose repression and the extent of

- 4 -

repression is correlated with the glucose uptake capacity. This suggests that the rate of glucose utilisation determines the strength of the relevant glucose signal (Gancedo, 1998, Microbiol. Mol. Biol. Rev., 62, p334-361).

However, it has been proposed that the extracellular (or intracellular) glucose concentration, rather than the glucose flux, triggers glucose repression (Meijer et al., 1998, J. Biol. Chem., 273, p24102-24107). If the glucose is sensed inside the cell then the transporters may have an indirect role not only in the generation of the initial signal but also in the maintenance of such a signal (Reifenberger et al., 1997, Eur. J. Biochem., 245, p324-333; Walsh et al., 1994, J. Bacteriol., 176, p953-958).

The intracellular glucose concentration has recently been shown to be much higher than reported previously, i.e. around 1.5 mM. This concentration is sufficient to reduce glucose influx by 50% (Teusink et al., 1998, J. Bacteriol., 180, p556-562). The authors of this study concluded that intracellular glucose is a strong candidate for regulation of glucose import and hence glycolysis.

During different external sugar concentrations, yeast cells exhibit high (K_m approx. 1-3 mM) or low (K_m approx. 10-50 mM) affinity sugar uptake systems (Bisson and Fraenkel, 1983, Proc. Natl. Acad. Sci. USA, 80, p1730-1734; Walsh et al., 1994, supra). Cells growing in low glucose media often display both a high affinity component and a low affinity component (Bisson and Fraenkel, 1983, supra). Glucose is transported into the yeast cell by facilitated diffusion through different specific carrier proteins (Bisson et al., 1993, Crit. Rev. Biochem. Mol. Biol., 28, p259-308).

Genetic studies have implicated a gene family, the HXT-family, including 20 homologous genes in encoding hexose transporters (Kruckeberg, 1996, Arch. Microbiol.,

- 5 -

166, p283-292; Diderich et al., 1999, J. Biol. Chem.,
274, p15350-15359; Ozcan and Johnston, 1999, Microbiol.
Mol. Biol., 63, p554-569). The *HXT* family belongs to
the major facilitator superfamily (Pao et al., 1998,
5 Microbiol. Mol. Biol. Rev., 62, p1-34). Different
members of the family are expressed to different levels
depending on the external glucose concentration
(Diderich et al., 1999, supra). *HXT1* is induced by high
glucose concentrations, whereas *HXT2*, *HXT4*, and *HXT6-7*
10 are induced at low glucose concentrations and *HXT3* is
induced irrespective of glucose concentration.
Furthermore, transcription of *HXT1-7* is correlated to
the extracellular glucose concentration. Also other
conditions, such as nitrogen availability and
15 aerobicity/anaerobicity affect the expression of members
of the *HXT* family (Reifenberg et al., 1995, Mol.
Microbiol., 16, p157-167; Reifengerger et al., 1997,
supra; Diderich et al., 1999, supra).

The *HXT* family also includes *GAL2* that encodes a
20 galactose transporter, which also transports glucose,
and *SNF3* and *RGT2*, encoding putative sensors of high and
low glucose concentrations, respectively (Diderich et
al., 1999, supra; Ozcan and Johnston, 1999, supra). The
putative sensor proteins probably serve as glucose
25 receptors and contains unusually long C-terminal tails
that are predicted to be in the cytoplasm (Ozcan et al.,
1996, Proc. Natl. Acad. Sci. USA, 93, p12428-12432;
Ozcan et al., 1998, EMBO. J., 17, p2566-2573).

Modification of *Saccharomyces cerevisiae* by
30 constructing DNA constructs which comprise a *HXT*-gene,
in particular by using *HXT1* and/or *HXT3*-genes, for
increasing the production of ethanol, in particular for
producing alcoholic beverages and liquor, is previously
known from EP-A-0 785 275.

35 However, *Saccharomyces* yeast that produce little or
no alcohol under aerobic conditions whilst still
exhibiting growth, are not known.

- 6 -

For several thousands of years yeast has been used for the preparation of alcoholic beverages and in the future this process might become even more important for the production of ethanol as a renewable fuel. However, many more products other than alcohol can potentially be produced by yeast from renewable resources. For example other valuable substances such as fine chemicals, non-alcoholic drinks and homologous and/or heterologous compounds such as proteins or low molecular metabolites could, and in many cases, are produced.

In order to compete successfully with production processes based on other techniques, e.g. using fossil raw material (such as oil, which may be used as the basis for producing some products, e.g. fine chemicals), the highest possible yield is required. A potential problem is that "good" carbon sources such as glucose often cause repression of genes required for synthesis of the desired substance. As a result the yield will be low or the product may not even be formed. To overcome, or at least minimise, these effects different cultivation techniques such as fed-batch cultivation or growth in a chemostat is often employed, which avoids general increases in the concentration of the carbon source, e.g. glucose, which could lead to repression.

It has however now surprisingly been found that by appropriate modification of the saccharide transport capabilities of the yeast, processing through the fermentation pathway of *Saccharomyces cerevisiae* can be avoided, even in the presence of high concentrations of saccharide as the carbon source, e.g. fermentable sugars such as glucose, but with maintenance of good growth and carbon source consumption. No other workers in the field have produced yeast with such advantageous properties.

The present invention thus offers a solution to the existing problems of processing through the fermentative pathway under aerobic conditions and high saccharide

- 7 -

levels since the yeasts containing the constructs of the invention seem to be relieved from the Crabtree effect, e.g. relieved from glucose repression. Hence, if fermentation is largely absent (e.g. via the absence of glucose repression), high yields of different substances can be obtained without resorting to sophisticated cultivation techniques.

The present invention thus relates to non-ethanol producing strains of *Saccharomyces cerevisiae* having specific hexose transporting properties, whereby changes in the hexose transporting gene provides one way of obtaining said non-ethanol producing property.

The invention described herein thus particularly relates to a chimeric construct between saccharide, e.g. glucose and/or galactose (preferably glucose), transporters, especially preferably between a high (for example HXT7) and a low (for example HXT1) affinity hexose transporter of the yeast *S. cerevisiae*.

Apart from traditional processes such as baker's yeast production, the industrial applications also include production of homologous and/or heterologous substances such as proteins or low molecular metabolites, as well as bulk and fine chemicals, food stuffs including yeast extracts, functional food and therapeutic agents. Another application area is the production of fermented non-alcoholic beverages.

Thus in a first aspect the present invention provides a modified *Saccharomyces* yeast which produces lower levels of alcohol, in particular ethanol, than wild-type yeast under aerobic conditions and saccharide concentrations of 5mM or more, preferably 2% glucose, and which exhibits a growth rate of at least 30% of the wild-type yeast.

Alternatively stated, the present invention provides a *Saccharomyces cerevisiae* strain having modified hexose transporting properties, which is non-ethanol producing under aerobic growth and high hexose

- 8 -

concentrations. Preferably said *Saccharomyces cerevisiae*, has heterologous and/or homologous expressed substances as described hereinafter.

Preferably, said yeast produces less than 50%, e.g. less than 30, 20 or 10% alcohol (particularly ethanol), especially preferably less than 5%, e.g. less than 3, 2 or 1% alcohol (particularly ethanol) compared to wild-type. Conveniently, this may correspond to alcohol (preferably ethanol) levels less than 0.6g/l, e.g. less than 0.25g/l, especially preferably, less than or equal to 0.15g/l, e.g. less than or equal to 0.12g/l, under the conditions of assay.

Preferably, said yeast exhibits a generation time of at least 30%, 35, 40, 45, 50, 60, 70 or 80% (preferably at least 60, 70 or 80%) relative to wild-type yeast, e.g. a generation time of less than 4.5h, e.g. less than 3.9, 3.5 or 3.0h or an equivalent growth rate.

In a particularly preferred feature therefore, the present invention provides a modified *Saccharomyces* yeast which produces less than or equal to 0.15g/l alcohol (in particular ethanol) under aerobic conditions and saccharide concentrations of 5mM or more, preferably 2% glucose, and which exhibits a growth rate of more than 50% of the wild-type yeast.

The modified yeast of the invention may exhibit reduced glucose consumption, e.g. less than 50%, e.g. less than or equal to 40% less than wild-type yeast, e.g. less than 5mmol glucose/(g biomass.h), but preferably consumes more than 20%, e.g. more than 30, 40 or 50% compared to wild-type.

Preferably the growth yield of the yeasts of the invention is at least 30%, e.g. from 30 to 120%, e.g. more than 40 or 50%, preferably more than 60, 80 or 100% of the wild-type yeast, e.g. more than 0.20, e.g. more than 0.35, 0.40 or 0.50g biomass/g glucose.

Preferably the oxygen consumption of yeasts of the

- 9 -

invention is improved relative to wild-type yeast, ie. is at least 100%, preferably at least 150, 175 or 200% relative to wild-type yeast, e.g. more than 2, 2.5, 3 or 4 mmol O₂/(g biomass.h).

5 Especially preferably the yeasts of the invention exhibit modified saccharide, e.g. hexose, e.g. glucose transporting properties. The transport of other saccharides, particularly galactose and/or maltose may also be affected.

10 Alteration of the saccharide transporting properties of yeast is conveniently achieved by introducing exogenous molecules related to naturally occurring transport molecules. Especially preferably chimeric constructs between portions of known
15 transporter molecules may be generated and incorporated into yeast cells and thereby affect their trafficking of saccharides and their use of the respiratory and fermentation pathways under aerobic conditions.

20 The Hxt-family and other saccharide transporters have very similar topology and are proteins with 12 transmembrane domains. It has now been found that combining portions from different molecules provides functional transporter molecules which exhibit altered transporting properties. Without wishing to be bound by
25 theory, it appears that such chimeras result in glucose derepression thus leading to enhanced use of the respiratory pathway and thus reduced alcohol production.

30 As described hereinafter in more detail, various chimeric molecules have been produced and integrated into the genome of *Saccharomyces cerevisiae*. In particular the development and testing of 2 modified yeast are described which contain chimeric constructs between portions of HXT1 and HXT7.

35 In the case of the first modified yeast (KOY.TM6 also referred to herein as KOY.TM6P), the fusion between the two genes has been effected in the region encoding transmembrane region 6 (TM6). This strain, KOY.TM6P,

- 10 -

shows derepressed properties during growth on glucose in the presence of oxygen i.e. only minute amounts of ethanol are formed (less than 0.12g/l during growth on 2% Glucose). Simultaneously, a relatively high growth rate with a generation time of 3.8h, sugar consumption rate 3.1-3.9 mmol/(g biomass.h) and growth yield of 0.41g biomass/g glucose is obtained.

The second modified yeast, KOY.TM4 (also referred to herein as KOY.TM4P) contains a construct in which the genes have been attached in the region encoding transmembrane region 4. This modified yeast shows growth properties very similar to those seen for KOY.TM6. It has a growth rate with a generation time of 3 to 3.9h and a yield of 0.34 g biomass/g of glucose.

Thus, in a preferred feature, yeasts of the invention contain a chimeric nucleotide sequence (a chimeric construct), preferably as defined hereinbelow, which is stably transformed into the genetic material of the yeast, wherein the construct comprises 2 or more nucleic acid sequences encoding different saccharide, e.g. glucose and/or galactose (preferably glucose), transporters, ie. the construct comprises at least a first sequence from the nucleotide sequence encoding a first saccharide transporter (or a sequence related to or derived therefrom) and a second sequence from the nucleotide sequence encoding a different second saccharide transporter (or a sequence related to or derived therefrom), wherein said saccharide is preferably glucose.

Especially preferably the construct is between at least a high and a low affinity hexose transporter, preferably of the yeast *Saccharomyces*, preferably *Saccharomyces cerevisiae*, which form said first and second saccharide transporters as described above. Preferably the transporters are selected from HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably from *Saccharomyces cerevisiae* or sequences

- 11 -

related to or derived from the sequences of such molecules. In particular, analogous and related sequences from other species or genera, e.g. from bacteria, plants or animals, may be used to produce the
5 chimeras.

Thus, the present invention preferably provides a *Saccharomyces cerevisiae* as described herein, comprising any combination of one or more of functional hexose transporters of the group HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c. Especially preferably,
10 said *Saccharomyces cerevisiae* comprises any combination of one or more of functional hexose transporters of the group HXT1 to HXT7.

The amino acid sequences of such molecules are as described in P32465 (HXT1), P23585 (HXT2), P32466 (HXT3), P32467 (HXT4), P38695 (HXT5), P39003 (HXT6), P39004 (HXT7), S50771 (HXT8), S50708 (HXT9), S48313 (HXT10), S49600 (HXT11), S50356 (HXT12), S50520 (HXT13), S63299 (HXT14), S67809 (HXT15), S57187 (HXT16), S63405 (HXT17), P13181 (GAL2), A31928 (SNF3), S67684 (RGT2),
20 S64624 (AGT1), S67812 (YDL247w) and S57190 (YJR160c) in which the accession numbers prefixed with S or A refer to those from the PIR Database and those prefixed with P refer to those from the Swiss-Prot database.

Also included within the scope of the invention are chimeras made from one or more sequences related to or derived from the above described amino acid sequences (or chimeric constructs made from the nucleotide sequences encoding one or more sequences related to or
30 derived from the above described sequences), e.g. one (or more) naturally occurring sequence may be combined with a sequence derived from a different naturally occurring molecule or a combination between 2 (or more) sequences each related to a different molecule may be
35 used.

Especially preferably, the nucleotide sequence encoding a chimera of, or for use in, the invention, may

- 12 -

comprise

one or more sequences or portions thereof
(particularly as described hereinbelow) of the
sequences encoding any one of HXT1 to HXT17, GAL2,
5 SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably
from *Saccharomyces cerevisiae*, as described above,
or a sequence which hybridizes to said
sequence or portion thereof under non-
stringent binding conditions of 6 x SSC/50%
10 formamide at room temperature and washing
under conditions of high stringency, e.g. 2 x
SSC, 65°C, where SSC = 0.15 M NaCl, 0.015M
sodium citrate, pH 7.2,
or a sequence which exhibits at least 80%,
15 preferably 90 or 95% e.g. at least 98%
sequence identity to said sequence or portion
thereof (as determined by, e.g. FASTA Search
using GCG packages, with default values and a
variable pamfactor, and gap creation penalty
20 set at 12.0 and gap extension penalty set at
4.0 with a window of 6 nucleotides),
or a sequence complementary to any of the aforesaid
sequences.

Such sequences or portions thereof may
25 comprise a first or second sequence as described
hereinbelow.

"Portions" as referred to above, preferably
comprise at least 30% of the wild-type sequence, e.g. at
least 50, 70 or 90% of the sequence, e.g. comprise 300
30 or more bases, preferably 500 or more or 600 or more
bases. However shorter portions may also be contemplated
when chimeras are made up of multiple portions. In such
case the portion may have for example 50 to 200 bases.
Portions as referred to in connection with amino acid
35 sequences comprise comparable lengths as those encoded
by the above described nucleotide sequences, e.g. 100 or
more residues, preferably more than 180 or 200 residues,

- 13 -

or shorter portions such as 15 to 65 residues.

Alternatively viewed, especially preferably the nucleotide sequences encoding a chimera of, or for use in, the invention, encodes an amino acid sequence which may comprise

5 one or more sequences or portions thereof (particularly as described hereinbelow) of the sequences of any one of HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably from
10 *Saccharomyces cerevisiae*, as described above, or a sequence which exhibits at least 80%, preferably 90 or 95% e.g. at least 98% sequence identity to said sequence or portion thereof (as determined by, e.g. using the
15 SWISS-PROT protein sequence databank using FASTA pep-cmp with a variable pamfactor, and gap creation penalty set at 12.0 and gap extension penalty set at 4.0, and a window of 2 amino acids).

20 Such sequences or portions thereof are encoded by a nucleotide sequences which may comprise a first or second sequence as described hereinbelow.

Preferably, where the nucleic acid sequences used to make the chimeras are related to or derived from the
25 naturally-occurring sequences (and preferably fall within the above described families), the related or derived sequences encode a functionally equivalent protein or precursor or portion thereof.

Preferably therefore, the invention extends to a
30 *Saccharomyces cerevisiae* as defined above, comprising any combination of one or more functional hexose transporters genes, the DNA sequences being derived from these genes by substitution, deletion, or addition of one or more nucleotides in such a way that the DNA
35 sequence still encodes a protein capable of transporting hexose(-s), e.g. glucose.

The invention also extends to chimeric constructs

- 14 -

encoding proteins which are functionally equivalent to those described above and below, e.g. which are formed by combination of naturally-occurring molecules (or sequences related to or derived therefrom, e.g.

5 functional equivalents), wherein that combination may be further modified, e.g. by substitution, deletion or addition, to provide a sequence encoding a functionally equivalent protein or precursor or portion thereof as defined hereinbelow, wherein preferably said
10 functionally-equivalent protein satisfies the identity defined above, e.g. has at least 98% identity to the sequence formed by the combination, or wherein the encoding sequence satisfies the identity or hybridizing conditions described above.

15 Thus in a further feature the invention provides a modified recombinant *Saccharomyces cerevisiae* as described herein expressing a modified gene (e.g. a chimeric construct as described herein) deriving from the genes of any one of the saccharide transporters
20 described herein, preferably HXT1 and HXT7, or derived transformants (e.g. functionally equivalent nucleic acid molecules) thereof.

Thus the present invention provides a nucleotide sequence comprising a chimeric nucleotide sequence as
25 described herein or a functionally equivalent nucleic acid molecule thereto, preferably satisfying the identity and/or hybridizing conditions described above, and modified yeast cells containing the same.

Preferably chimeras are made between low affinity
30 transporters, preferably HXT1 or HXT3 and high affinity transporters, preferably HXT2, 4, 6, 7 (especially preferably HXT6 or 7) or GAL2P.

Particularly preferably chimeric constructs are made between HXT1 and HXT7 or sequences related to or
35 derived therefrom, and used to transform yeast to provide the yeast of the invention. Preferably N-terminal portions of HXT1 are conjugated with C-terminal

- 15 -

portions of HXT7, although the alternative form with HXT7 at the N-terminus and HXT1 at the C-terminus is also included within the scope of the invention.

Thus, the nucleotide sequence encoding the chimera
5 (ie. the chimeric construct) comprises a sequence having the form:

A - B

10 wherein

A is a first component (ie. the first sequence as described hereinbefore) comprising nucleotide bases w to x;

15 B is a second component (ie. the second sequence as described hereinbefore) comprising nucleotide bases (x+y) to z;

wherein A and B are derived from distinct molecules, e.g. HXT1 and HXT7, ie. from the nucleotide sequences of different saccharide
20 transporters or from sequences related to or derived therefrom;

w is a first position within the nucleotide sequence from which said first component is derived (e.g. HXT1 or HXT7 or a comparable sequence as
25 described above), which is less than x, preferably from 1 to 300, e.g. 1 to 50, especially preferably 1 to 10, e.g. 1;

x is a second position within the nucleotide sequence from which said first component is derived and is greater than w and is preferably a number
30 from 300 to 1250, e.g. 500 to 850;

y is an integer, preferably less than 10 , e.g. less than 5, e.g. less than 3, e.g. 1;

35 x+y is a first position within the nucleotide sequence from which said second component is derived (e.g. HXT1 or HXT7 or a comparable sequence as described above);

- 16 -

and z is a second position within the nucleotide sequence from which said second component is derived and is greater than x+y, preferably from 800 to 1713, especially preferably 1200 to 1713, e.g. 1600 to 1713, e.g. 1675 to 1713; wherein said values refer to the position within the nucleotide sequence of said saccharide transporter, e.g. HXT1 or HXT7 or a comparable sequence thereof.

10

The transporter molecules of *Saccharomyces cerevisiae* comprise 12 transmembrane sequences. In a preferred feature, the point of junction between the 2 or more portions which together form the chimera falls within the sequence of the 3rd to 9th transmembrane stretches. Thus, preferably x is a position in the sequence encompassed by the third to ninth transmembrane stretches of HXT1 or HXT7 or a comparable sequence, especially preferably 400 to 900, e.g. 525 to 800, for example 525-575 and/or 720-770 especially preferably 545 to 560 and/or 735 to 750 and y is preferably 1 and z is preferably as described above.

Preferably chimeras of the invention have a total of 12 transmembrane domains (e.g. w is less than 10 and x is from 1675 to 1713). This may be achieved by for example combining some of the 12 transmembrane domains (e.g. domains 1 to 3-9, or parts thereof) from a first transporter and the remainder (3-9 to 12, or parts thereof) from a second transporter. However, more or fewer transmembrane domains are also contemplated and linker groups may optionally appear between one or more of the transmembrane domains. Thus, preferably said chimeras of the invention comprise from 6 to 18 transmembrane domains, e.g. 10 to 14, which are derived from 2 or more transporter molecules as described hereinbefore.

35

Said chimeras described above may contain more than

- 17 -

2 components, e.g. multiple portions, e.g. 2 or more sequences of the nucleotide sequence of one or more transporter molecules or sequences from the nucleotide sequences of more than 2 transporters as described herein, in which case the portions are provided in parallel, preferably to retain the transmembrane structure, e.g. 10-14, preferably 12 transmembrane structure, optionally with one or more linker groups between said portions. A linker group may also be inserted between A and B above (ie. y may be more than 1), providing this does not affect the functionality of the chimera.

Especially preferably x is 551 or 741, w and y = 1 and Z = 1713. Alternatively, x may be 668. Chimeric polypeptides encoded by such nucleic acid molecules are set forth in Seq. ID Nos. 1 and 2. Such sequences, sequences comprising them, functionally equivalent polypeptides (preferably satisfying the identity requirements described above) and nucleic acid molecules containing a nucleotide sequence encoding the same, form preferred aspects of the invention. In a preferred feature, said encoding nucleic acid sequences are as set forth in Sequence ID Nos. 3 or 4. Yeast cells expressing these forms also form preferred aspects of the invention. In particular, a further aspect of the invention provides a modified recombinant *Saccharomyces cerevisiae* as described above denoted *Saccharomyces cerevisiae* KOY.TM4P or KOY.TM6P or derived transformants thereof, particularly having the deposition number DSM 13832 or DSM 13555, respectively.

Nucleic acid molecules comprising nucleotide sequences as described above, sequences encoding chimeric proteins as described above and complementary sequences thereto form further aspects of the invention. Proteins or polypeptides comprising a sequence encoded by such nucleic acid molecules form further aspects of the invention. In addition, the invention extends to

- 18 -

functionally equivalent proteins as described hereinbefore, in addition to those in which the amino acids have been chemically modified, including by deglycosylation or glycosylation. In particular, these variant proteins may be prepared by post-synthesis/isolation modification of the substrate without affecting functionality, e.g. certain glycosylation, methylation etc. of particular residues. Non-standard amino acid may be used, such as α -aminobutyric acid, penicillamine, pyroglutamic acid or conformationally restricted analogs, e.g. such as Tic (to replace Phe), Aib (to replace Ala) or pipecolic acid (to replace Pro).

Nucleic acid molecules according to the invention may be single or double stranded DNA, cDNA or RNA, preferably DNA and include degenerate, substantially identical and hybridizing sequences as described before. Ideally however genomic DNA or cDNA is employed.

Such exogenous molecules may be introduced into yeast cells by any appropriate means. Suitable transformation or transfection techniques are well described in the literature. The nucleic acid molecules described above may be operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule. In particular, appropriate nucleic acid molecules may be introduced into vectors for appropriate expression in the cell. Alternatively, the naked DNA molecule may be introduced directly into the cell. Conveniently, transformation of yeast cells as described herein is effected by the lithium acetate transformation method (Burke et al., 2000, CSHL Press, p103-105) or by freeze-thaw or spheroplast methods or other appropriate techniques (see e.g. Dohmen et al., 1991, Yeast, 7, p691-692).

Appropriate expression vectors include appropriate control sequences such as for example translational

- 19 -

(e.g. start and stop codons, ribosomal binding sites) and transcriptional control elements (e.g. promoter-operator regions, termination stop sequences) linked in matching reading frame with the nucleic acid molecules of the invention. Appropriate vectors may include plasmids and viruses (including both bacteriophage and eukaryotic viruses). Suitable viral vectors include baculovirus and also adenovirus, adeno-associated virus, herpes and vaccinia/pox viruses. Many other viral vectors are described in the art.

A variety of techniques are known and may be used to introduce the vectors into cells for expression. Such vectors and eukaryotic or prokaryotic cells, particularly yeast cells, into which said vectors have been transfected form further aspects of the invention.

As mentioned above, nucleic acid molecules of the invention, or vectors comprising the same, may be introduced into any eukaryotic or prokaryotic cells, but particularly yeast cells, especially preferably *Saccharomyces cerevisiae*. Such cells may correspond to wild-type cells. However, conveniently, said cells may be modified (e.g. represent an altered recombinant form) even prior to inclusion of the nucleic acid material relating to the chimeric molecules.

Thus in a preferred embodiment, the phenotype of the wild-type cell is modified to produce a null strain in terms of saccharide, particularly glucose, transporting molecules, ie. to provide a null strain without or with severely limited saccharide transporting properties, e.g. exhibiting a glucose uptake preferably less than 2nmol glucose/min/mg biomass. This may be achieved by modification of the genotype to remove or alter the genes encoding one or more of HXT1-17, Gal2, Stl1 and 3 maltose transporters with glucose affinity and transport properties, namely AGT1, YDL247w/MPH2 and YJR160c/MPH3 or by altering the expression of one or more of those genes (e.g. by deleting one or more

- 20 -

necessary transcription or translation factors) or by impairing the function of one or more of the expressed transporters. Conveniently, all of the above described genes, control systems affecting these genes or
5 expressed proteins may be altered or impaired such that no active transporters are available for transport. However, alternatively a sub-set of transporters or their genes or expression thereof may be affected, preferably at least HXT1-4,6,7 and GAL2. These effects
10 may be achieved as described above by for example altering the genes of the transporters, by affecting the transcription or translation of the genes, or by dominant negative mutation methodologies. The nucleic acid molecule encoding the chimera as described herein
15 may thereafter be introduced into the null strain to provide a saccharide transporting phenotype.

Constructs and particularly modified *Saccharomyces* strains having the above described properties have great potential as tools for preparative processes in which
20 metabolic pathways can be manipulated and undesirable side-products avoided. A yeast strain that does not produce any ethanol has been sought for a long time. The novel strains will therefore serve as invaluable tools in future efforts of characterization, e.g. to
25 find an explanation for the repression mechanism during aerobic growth on glucose in *S. cerevisiae*. Further, a strain that does not produce any ethanol even when grown on high sugar concentrations during aerobic batch cultivation is also of considerable interest in terms of
30 exploitation for industrial use.

Thus, *Saccharomyces* cells of the invention may be used in any processes in which the production of alcohol and other products produced during fermentation is undesirable. Such processes include for example the
35 production of non-alcoholic high or low molecular metabolites, or low or high molecular weight compounds such as bulk and fine chemicals, food stuffs, functional

- 21 -

food, therapeutic agents and non-alcoholic or low alcohol beverages.

These products may be produced by unmodified yeast of the invention, e.g. non-alcoholic or low alcohol beverages may be produced using appropriate saccharide containing carbon sources, e.g. fruit juices. In this way, low or non-alcoholic wines, beers or other drinks may be generated. Non-alcoholic beverages preferably have the alcohol levels defined herein. However, in a preferred feature, a beer is produced with alcohol levels of less than 1% alcohol w/v, especially preferably <0.5%, and similarly wine may be produced with alcohol levels of less than 10%, especially preferably less than 2.5 or 1% alcohol w/v.

Alternatively, such products may be produced by the introduction of exogenous genetic material which encodes a product of interest. Alternatively, exogenous genetic material may be used which influences the metabolic activity of the cell, thus resulting in the production of, or increased production of, a product of the yeast cell, by biasing the metabolic processes of the cell to produce (or increase production of) a desired product. In a further alternative, endogenous genetic material may be modified to influence the metabolic activity of the cell and thus favour production of a desired product.

The products of the above described genetic engineering may occur naturally in said yeast cells prior to genetic engineering, but are made to exhibit improved production after said engineering. In such cases the exogenous material may for example encode a protein involved in the metabolic process (either directly or indirectly), or an inhibitor of a catabolic process, or may provide regulatory control of the expression of such proteins, e.g. an inducible or constitutive promoter.

Modification of endogenous genetic material may be

- 22 -

performed to affect a metabolic process, e.g. a sequence encoding a protein or an inhibitor or a sequence providing regulatory control may be modified to thereby effect the functions of that component.

5 The products of metabolic engineering may however not occur in wild-type yeast, and in which case said engineering may result in expression of one or more polypeptides which is the product, or which makes production of the desired product possible.

10 In a preferred aspect however, the product is an entity capable of being produced by said yeast cell (prior to inclusion of constructs of the invention) but which is produced in increased quantities after the introduction of exogenous genetic material, or
15 modification of endogenous genetic material, as described above. Thus, in a preferred feature, products which may be produced by yeast of the invention are amino acids, peptides, polypeptides, sugars, small polyols and carbon dioxide, to mention but a few.

20 Thus, exogenous or endogenous genetic material, encoding a product of interest or part thereof, or a polypeptide which directly or indirectly facilitates production of a product of interest, or exogenous or endogenous genetic material influencing the expression
25 of the same, may be inserted into, or modified in, yeast cells of the invention, e.g. optionally by stable transformation into the cells' genome in the case of exogenous genetic material. The cells may then be grown under high saccharide concentrations under aerobic
30 conditions and the product thus formed harvested.

 Thus, in a yet further aspect the present invention provides a method of inserting exogenous material into a yeast cell as described above, to produce a yeast cell of the invention containing exogenous genetic material,
35 said method comprising at least the steps of introducing said genetic material, preferably contained within a vector, into said cell, e.g. by transformation.

- 23 -

Preferably the exogenous material encodes, or controls the expression of, a product which is, or which enables the production of, a product. Alternatively stated the exogenous material encodes said product or portion thereof or encodes a polypeptide (or part thereof) which facilitates the direct or indirect production of said product or portion thereof, or affects the expression of said product or polypeptide. Such a product may be a high or low molecular metabolite, or a low or high molecular weight compound such as a bulk or fine chemical, a food stuff, a functional food or a therapeutic agent, e.g. as described above. Cells obtainable by this method form further aspects of the invention.

These further modified yeast may then be used to produce the desired product which can then be isolated from the yeast cells. Thus in a further aspect the present invention provides the use of a *Saccharomyces cerevisiae* having modified hexose transporting properties and which is non-ethanol producing under aerobic conditions and high hexose concentrations, in the preparation and manufacture of substances including low or high molecular weight metabolites, preferably in the preparation and manufacture of bulk and fine chemicals, food stuffs, functional food, therapeutic agents or non-alcoholic beverages.

Alternatively viewed the invention further provides a method of preparing a product, e.g. a polypeptide, amino acid, sugar or polyol in a yeast of the invention containing the genetic material as described above, said method comprising growing said yeast cells under aerobic conditions in the presence of high saccharide, preferably glucose, concentrations. In an alternative preferred feature, as mentioned above, products are produced by yeasts of the invention which have not been further modified, but which produce low levels of alcohol and thus when grown on an appropriate medium

- 24 -

produce products of interest, e.g. low or non-alcoholic beverages. In a preferred feature the products thus produced as described above are isolated and form further aspects of the invention.

5

In determining the growth, alcohol production, saccharide consumption or other parameters described herein the following test conditions are used. These parameters are assessed during the period of exponential growth under aerobic (O_2 non-limiting) conditions at 30°C, in the medium used by Verduyn et al. (1992, Yeast, 8, p501-517) at pH 5.00 in the presence of 2% glucose, with a starting culture of 0.3 to 0.7g dry biomass/l (preferably 0.3) in 1.5l fermentors, stirred at 1500rpm and an air inflow of 0.5 volume of air per vessel volume per minute (vvm).

15

Biomass content (dry weight) is determined as follows: 5 ml is removed from the culture and centrifuged for 5 minutes in pre-weighed dry weight tubes at sufficient rpm to pellet substantially all the cells. The pellet is washed once with 5 ml 0.9% NaCl and re-pelleted. The pellet is dried for 24 hours at 110°C before temperature equilibration and weighing.

20

Continuous gas analysis is effected using a carbon dioxide and oxygen monitor type 1308, Bruel and Kjaer, Naerum, Denmark; e.g. to calculate oxygen consumption rates.

25

Glucose and ethanol determinations are made in the samples as follows: 1.5 ml samples of the culture are centrifuged at 15000g for 1 minute and the resulting supernatants frozen at -20°C until analysis. Concentrations are determined using enzyme combination kits from Boehringer Mannheim, GmbH, Germany.

30

As used herein, a "modified" yeast refers to one which has been derived from or is related to a wild-type yeast but exhibits phenotypic and preferably also genotypic variation thereto. Preferably the genotype

35

- 25 -

has been modified, particularly in relation to genes encoding saccharide transporting molecules, which results in an altered phenotype. Conveniently this may be achieved by recombination to remove and/or modify
5 existing genetic information and/or alter and/or integrate exogenous genetic sequences. Preferably the modification relates to at least the inclusion of chimeric nucleic acid molecules as described herein. Additional modifications may however also be
10 contemplated, preferably those which further affect the saccharide transporting molecules, e.g. by the creation of yeast cells which are unable to transport glucose or exhibit a severely restricted capacity to do so, prior to insertion of the chimera. These recombinant organisms
15 form preferred features of the invention. Furthermore, additional genetic modifications may be contemplated, e.g. to introduce genetic material encoding a desirable product or portion thereof.

As used herein "wild-type" refers to the yeast
20 strain from which the modified yeast is originally derived or to which it is related. When reference is made to % alcohol, growth etc. of yeast of the invention relative to wild-type, said wild-type refers to the unmodified, naturally occurring, yeast, prior to
25 insertion of constructs of the invention or modification of the genome in any way, ie. does not refer to for example a null strain into which the construct is inserted, but rather refers to the naturally-occurring yeast from which the null strain is generated. Thus
30 when the invention relates to modified *Saccharomyces cerevisiae* yeast, the wild-type is the *Saccharomyces cerevisiae* strain that has been modified. Wild-type sequences refer to those occurring in wild-type microorganisms such as those defined hereinbefore.

35 "Saccharomyces" refers to the genus of the wild-type yeast which is modified. "*Saccharomyces cerevisiae*" refers to the particular species which is preferably

- 26 -

modified, and includes all strains falling within that particular species.

As used herein, "alcohol" refers to the production of alcohols such as glycerol and ethanol. However, in the tests described herein, the level of ethanol is tested. Glycerol contributes only a small proportion of the total alcohol content relative to ethanol. "Non-ethanol producing" refers to yeast producing the amounts of ethanol described above, e.g. less than or equal to 0.12g/l, under the conditions of assay.

The g/l levels of alcohol, in particular ethanol, refers to the amount produced per litre of culture under the test conditions when assessed continually at discrete time points. Maximum levels are generally achieved just prior to glucose depletion during batch cultivation.

"Aerobic conditions" refers to culture conditions which are not limiting for oxygen and thus allow use of respiratory pathways. "Aerobic growth" refers to growth, e.g. as measured by increasing optical density at 610nm and increase in biomass content under such conditions.

A "transporter" refers to a molecule responsible for transfer of the molecule to be transported from the extracellular culture medium into the cell or vice versa, ie. effecting its passage, e.g. diffusion, across the plasma membrane. However, in producing chimeras of the invention, saccharide receptors such as SNF3 and RGT2 and sequences related to or derived therefrom may also be used and fall within the scope of the definition of transporters insofar as it relates to transporters which may be used to make chimeras.

"Hexose" or "saccharide" transporting properties refers to the ability of the modified yeast of the invention to take up saccharide from the extracellular culture medium.

A "functional hexose transporter" refers to a

- 27 -

transporter molecule which may be a naturally occurring molecule or a functionally equivalent variant as described herein, which is able to transport a saccharide as described above. In reference to functional hexose transporters which may be used to make chimeras of the invention, in line with the definition of transporters, such functional hexose transporters also extend to molecules which have the function of saccharide receptors.

By "hexose transporter gene" is meant a gene encoding a protein which effects the passage, e.g. diffusion, of hexoses across the plasma membrane, for example the HXT4, HXT5, or HXT6 genes.

"Saccharide" refers to mono-, di- or polysaccharides which may be used as a carbon source by wild-type or modified *Saccharomyces* yeast of the invention. Preferably the saccharides are monosaccharides, particularly preferably glucose, fructose, mannose or galactose, or disaccharides such as maltose. Preferably such saccharides are in the naturally occurring D form. For use under test conditions, naturally occurring underivatized D form saccharides, such as D-glucose, are employed. "Hexose" refers to monosaccharides such as those mentioned above, e.g. glucose, fructose and galactose.

"Growth rate" as referred to herein is mathematically related to generation time and has the relationship: $\mu = \ln(2)/G$; wherein μ is the specific growth rate, and G is the generation time. As such, values for % generation time rate relative to wild-type yeast similarly provide preferred % growth rates.

"Generation time" is measured in hours and refers to the doubling time, ie. the time taken for each generation to be produced during culture, wherein the generations are assessed by reference to increases in the dry weight of the biomass. Other experiments have been performed which determine generation time by

- 28 -

reference to readings at OD₆₁₀. In such cases TM6 yields a value of 2.9 and TM4 a value of 2.5. Definitions provided in the text however refer to the values determined using the dry weight measurement described above.

The "glucose consumption rate", refers to the amount of glucose consumed from the external medium during the test conditions, and is thus assessed by measurement of the glucose in the medium at at least 2 time points and calculation of the glucose consumed in the time between those time points. This value is provided in mmol glucose/(g biomass.h), wherein the g biomass refers to the dry mass of yeast in the culture.

"Biomass" refers to the mass attributed to the dry mass of the yeast in the culture.

The term "high hexose" concentrations used in the context of growing the *Saccharomyces cerevisiae* refers to any hexose concentration exceeding 1mM, preferably exceeding 5 mM present in the media, especially preferably more than 50mM, e.g. equal to or more than 1 or 2% hexose, preferably glucose. In the test conditions however a value of 2% glucose, ie. 111mM is used. Similar definitions apply to high saccharide or glucose concentrations. Products as described herein may be produced at various high levels of saccharide, e.g. more than (or equal to) 1, 2, 5, 10 or 20% saccharide. In particular, the higher saccharide levels may be used when producing the beverages described herein.

As used herein, "exponential growth" refers to an exponential rate of doubling the biomass.

As used herein a "chimera" refers to a nucleic acid molecule or polypeptide comprised of two or more sequences (component sequences) derived from two or more different molecules, preferably two sequences each derived from a different molecule. Thus such chimeras provide the result of a combination of such sequences.

- 29 -

As described hereinbefore said component sequences (or the parent sequences of which they are a portion) may be naturally occurring or may be related to or derived from such naturally occurring sequences. Whilst conveniently
5 the separate component sequences may be combined together by linking the respective sequences to one another, alternatively, particularly if the sequences are highly homologous, alternative techniques may be used to obtain the chimera, e.g. by mutation of
10 appropriate sites within a particular molecule to arrive at a sequence which in effect reflects a chimera between two distinct sequences.

A "chimeric construct" refers to a nucleic acid molecule comprising at least a nucleotide sequence
15 encoding or providing a chimera as defined above, optionally additionally comprising flanking sequences optionally containing functional elements, e.g. promoter sequences.

"Stably transformed" refers to the inclusion
20 (preferably insertion into the genome) of the construct of the invention into yeast cells as described herein, such that the encoding region of said construct may be expressed, and the construct or part thereof encoding a chimera of the invention is present in the progeny of
25 the yeast cell.

As used herein, "low affinity" transporters refer to those which bind glucose with a K_m of more than 20mM, e.g. from 50-100mM under the conditions described herein in Example 1. "High affinity" transporters refer to
30 those having a K_m of less than 20mM, preferably less than 10mM, e.g. 1-2mM.

Sequences which are "related to or derived" from nucleotide or amino acid sequences described herein refer to sequences which have been modified relative to
35 those sequences, e.g. by substitution, deletion or addition. Preferably such sequences are functional equivalents as described herein. Especially preferably

- 30 -

they have the stated identity or hybridizing properties as described hereinbefore.

"Functionally-equivalent" proteins as used herein refers to proteins related to or derived from the native
5 or naturally-occurring protein, where the amino acid sequence has been modified by single or multiple amino acid substitution, addition and/or deletion, but which nonetheless retain the same function, ie. are capable of transporting (or when used to make chimeras act as a
10 receptor for) one or more saccharide molecules, e.g. glucose, to a lesser or greater extent than the naturally occurring molecules. Such proteins are encoded by "functionally-equivalent nucleic acid molecules" which are generated by appropriate
15 substitution, addition and/or deletion of one or more bases. Preferably the functionally-equivalent protein or nucleic acid molecule satisfies the identity and/or hybridizing conditions as set forth hereinbefore.

Within the meaning of "addition" variants are
20 included amino and/or carboxy terminal fusion proteins or polypeptides, comprising an additional protein or polypeptide fused to the chimeric portion.

Such functionally-equivalent variants mentioned above include natural biological variations (e.g.
25 allelic variants or geographical variations within a species or alternatively in different genera, e.g. plants, animals or bacteria) and derivatives prepared using known techniques. For example, nucleic acid molecules encoding functionally-equivalent proteins may
30 be produced by chemical synthesis or in recombinant form using the known techniques of site-directed mutagenesis including deletion, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids. In particular nucleic acid molecules encoding functionally
35 equivalent protein variants for the production of chimeras in accordance with the invention extend to analogues in different genera or species than the

- 31 -

specific molecules mentioned herein.

"Precursors" of the naturally occurring proteins may be larger proteins which would be processed, e.g. by proteolysis to yield the substrate. Such precursors may
5 take the form of zymogens, ie. inactive precursors of enzymes, activated by proteolytic cleavage.

"Portions" of functionally equivalent proteins are as described above, and do not themselves necessarily exhibit the activity of the parent molecule. Preferably
10 these portions satisfy the identity (relative to a comparable region) or hybridizing conditions mentioned herein. Portions of products refers to portions which when combined with other entities form the desired product.

15 "A polypeptide or part thereof which facilitates the direct or indirect production of a product or portion thereof" refers to a molecule, or a part of a molecule or complex, which on expression in a yeast cell of the invention results in the production of the
20 product or part thereof, e.g. by altering or contributing to pathways which affect its production.

A polypeptide "affects the expression" of a product or polypeptide when it exerts a regulatory control on said expression.

25

The following Examples are given by way of illustration only in which the Figures referred to are as follows:

30 Figure 1 shows oxygen consumption and carbon dioxide production under different phases of the growth cycle of *S. cerevisiae* of the prototropic KOY.PK2-1C83 wild-type strain;

35 Figure 2 shows oxygen consumption and carbon dioxide production under different phases of the growth cycle of *S. cerevisiae* of the prototropic TM6-expressing strain;

- 32 -

Figure 3 shows a semilog-plot of the optical density versus time giving the measure of biomass growth during aerobic growth on glucose by the TM6-expressing strain;

5 Figure 4 shows a continuous on-line plot of the ratio between the carbon dioxide production rate and the oxygen consumption resulting in continuous monitoring of RQ during aerobic growth on glucose of the TM6-expressing strain. Measurements during the first 20 hrs
10 should not be considered because of limiting sensitivity;

Figure 5 shows on-line heat-production measurement for KOY.TM4P;

15 Figure 6 shows a semilog-plot of the optical density versus time giving the measure of biomass growth on glucose by the TM4-expressing strain; and

20 Figure 7 shows a semilog-plot of the biomass(g/l)/time(h) for A) TM6 and B) TM4.

Example 1: Production of modified *Saccharomyces cerevisiae* strains containing chimeras of HXT1 and HXT7

The yeast HXT-family has clear similarities to the mammalian Glut1. Since this protein has 12 transmembrane domains with N- and C-terminus located in
30 the cytoplasm (Mueckler, 1994, Eur. J. Biochem., 291, p713-725) it is very likely that yeast hexose transporters have similar topology in which the N and C termini are intracellularly located and the sequence joining the termini passes back and forth through the
35 membrane to provide 12 transmembrane regions linked together by intracellular or extracellular loops of various lengths. Chimeras were produced which contained

- 33 -

HXT1 at the N-terminus fused together with HXT7 in the transmembrane region. For example, KOY.TM6P (present innovation) which is fused in transmembrane region 6 is identical to HXT1 from the N-terminus up to the middle of transmembrane region 6 while the rest of the protein is equivalent to HXT7.

This gives in total 12 constructs named TM1 to TM12 which have all been integrated into the genome.

10

Materials and methods

Strains

A CEN.PK strain with deletions for the genes of the sugar transporters *HXT1-7* has been shown to still grow on glucose (Wieczorke et al., 1999, FEBS Lett., 464, p123-128). Because of this the additional *HXT* genes (altogether 17 genes), as well as further genes (see below) have been deleted in order to obtain a true null strain in terms of glucose transport (Wieczorke et al., 1999, supra) - EBY.VW4000. Although the physiological roles of *HXT8-17* have not been described so far (except that *HXT9* and 11 have been described to be involved in Multi-Drug-Resistance), they are certainly not silent during all conditions. A *hxt5* deletion mutant does not show a clear phenotype in glucose media. It is expressed in glucose deprived cells, probably in order to ensure rapid utilisation of the sugar when it becomes available. The complete null strain is useful, since re-introduction of one or several specific hexose transporter from yeast or even from other organisms can be used to study up-take kinetics and sugar consumption kinetics of specific transporters. Hence, the null strain is in the first place a tool to study the properties of specific yeast or heterologous hexose transporters.

- 34 -

The wild-type strain CEN.PK2-1C, has the following genetic markers *Mata leu2-52*, *112ura3-52*, *trp1-289*, *his3-Δ1*, *MAL2-8c* *SUC2*. This strain was made prototrophic (KOY.PK2-1C83) by introducing the marker genes one by one by transformation. The "null mutant" EBY.VW4003 (*Mata leu2-52*, *112ura3-52*, *trp1-289*, *his3-Δ1*, *MAL2-8c* *SUC2* *Hxt1-17Δ*, *Gal2Δ*, *Stl1Δ*, 3 deleted maltose transporters with glucose affinity, namely *AGT1*, *YDL247w* and *YJR160c*; genomic cassette *Pro-HXT7::URA3*) is unable to grow on any concentration of glucose. The deletions in the strain to provide the "null strain", which is deleted in all known hexose transporters and putative transporters, was constructed using the *lox P/Cre* recombinase system (Gueldener et al., 1996, Nucl. Acids Res., 24, p2519). The strain was made prototrophic (KOY.VW100) by transformation.

Chimeras

Chimeras between *HXT1* and *HXT7* were made using the PCR based method "in vitro overlap-extension" (Higushi et al., 1981, Nucl. Acids Res., 16, p7351-7367; Ho et al., 1989, Gene, 71, p51-59). The parts to be fused together were first amplified separately but with ends that can anneal with each other. In the second PCR step, flanking primers were used to only allow amplification when annealing of the two separate products had taken place.

For the preparation of TM4, the *HXT1* part of TM4 was amplified from plasmid *pTHXT1-2* (Reifenberger et al., 1997, supra describes the production of *pTHXT1-1* in which the *HindIII* insert is in the reverse orientation compared to *pTHXT1-2*) using the following primers:

Forward primer:

5'-CAAAGAATAA ACACAAAAC AAAAAGTTTT TTTAATTTTA
ATCAAAAAT GAATTCAACT CCCGATCTAA TA-3'

- 35 -

Reverse primer:

5'-GGAGATAAAA CGGCAATACC ACCGACACCT AAACCA-3'

5 The HXT7 part of TM4 was amplified from plasmid P21
(Reifenberger et al., 1995, Mol. Microbiol., 16, p157-
167) using:

Forward primer:

5'-TGGTTTAGGT GTCGGTGGTA TTGCCGTTTT ATCTCC-3'

10 Reverse primer:

5'-TTTGTAGACG TGGGTCTGCA GGCA-3'

15 For the preparation of TM6, the HXT1 part of TM6 was
amplified from plasmid pTHXT1-2 using the following
primers:

Forward primer:

5'-CAAAGAATAA ACACAAAAC AAAAAGTTTT TTAAATTTTA
ATCAAAAAAT GAATTCAACT CCCGATCTAA TA-3'

20 Reverse primer:

5'-CTGGAACAAA TGTCATACCA CCAATCATAA ATAAGGCCCA G-3'

25 The HXT7 part of TM6 was amplified from plasmid P21
using:

Forward primer:

5'-CTGGGCCTTA TTTATGATTG GTGGTATGAC ATTTGTTCCA G-3'

Reverse primer:

5'-TTTGTAGACG TGGGTCTGCA GGCA-3'

30

35 The products from the first two separate reactions were
mixed and a PCR run in which the forward primer from the
HXT1 reaction and the reverse primer from the HXT7
reaction was used. Since the products from the two
first reactions are made in such a way that they have
overlapping regions, one obtains a product in which the
HXT1 and HXT7 parts are fused together.

- 36 -

The construct KOY.TM6P was made by fusing HXT1 and HXT7 in the sixth trans membrane region, The N-terminus consists of bp 1-741 of HXT1 and the C-terminus of 742-1713 of HXT7. The construct TM4 was made by the same method used for the TM6 construct but the two genes were fused in TM-region 4. For TM4 this is bp 1-551 of HXT1 and 552-1713 of HXT7.

These constructs were introduced into the KOY.VW100 strain, which was made prototrophic by introducing URA3 prior to said introduction. The cassette used in the null-mutant is located in the former *HXT3-6-7* gene cluster and contains the constitutive promoter of *HXT7::K. lactis URA3::HXT7* terminator and was prepared as follows.

Construction of the genomic expression cassette
(Sequence ID No.: 5):

A 392 bp *HXT7* promoter fragment was integrated into the genome of strain EBY.VW4000 (Wieczorke et al., 1999, supra) into the former *HXT3-6-7* gene cluster region by using a modification of the PCR targeting technique, resulting in a very strong and constitutive *HXT7* promoter-terminator expression cassette (see Hauf et al., 2000, Enzyme Microb. Technol., 26, p688-698). Part of the *HXT7* promoter together with part of the *HXT7* coding region from -392 to +30 was amplified by PCR with primers PROHXT7-1 and PROHXT7-2 (see below), and plasmid p21-PST (Reifenberger et al., 1995, supra) as a template. The PCR product was cleaved with *SpeI* at both ends and cloned in the correct orientation into the *SpeI* site of plasmid pUG6 (Gueldener et al., 1996, supra) behind the second *loxP* site, resulting in plasmid pUG6-kPHXT7. This plasmid was then used as a template to generate by PCR with primers INTPH7-1 and INTPH7-2 a DNA molecule consisting of a *kanMX-HXT7p* marker cassette flanked by short homology sequences to the *HXT3* promoter

- 37 -

(-770 to -720) and *HXT7* terminator regions. The 2.4 kb PCR product was transformed into strain EBY.VW4000 (whose *HXT3-6-7* gene cluster is replaced by a *loxP* site), selecting for resistance to G418 (200 mg liter⁻¹) on YPMaltose agar plates, and used to replace the *HXT3* promoter-*loxP* region by the *kanMX-HXT7p* cassette. After transformation with plasmid pSH47, the *kanMX* marker was removed as described (Gueldener et al., 1996, supra), resulting in strain EBY.VW4002.

The *HXT7* gene was amplified by PCR from plasmid p21-PST with primers C1-IHXT7 and C4-IHXT7. The PCR product containing short homology sequences to the *HXT7* promoter-terminator expression cassette of strain EBY.VW4002 was transformed into this strain, selecting for growth on YPGlucose agar plates. Integration into the genomic expression cassette by homologous recombination resulted in strain JBY02 (*HXT7+*). To construct an FOA(5-fluoroorotic acid)-counterselectable marker-expression cassette in strain EBY.VW4002, the *K. lactis* *URA3* ORF was PCR-amplified from strain MS7-62 (gift of C. Falcone, Rome) with primers I-KURA31 and I-KURA32 (see below), resulting in a DNA-fragment with the *KlURA3* ORF flanked by short homology regions to the *HXT7* promoter and *HXT7* terminator. The DNA fragment was transformed into strain JBY02 selecting for growth on a synthetic medium without uracil and with maltose as the carbon source, resulting in strain EBY.VW4003 containing a genomically integrated *HXT7* promoter^(-392 - +1) - *KlURA3* - *HXT7* terminator expression cassette. This strain was made prototropic (KOY.VW100) by transformation.

PROHXT7:

35 5'-GGACTAGTGA TATCTCTCGT AGGAACAATTTTCGG-3'

PROHXT7-2:

5'-GGACTAGTTG CTCTGCAATAGCAGCGTC-3'

- 38 -

INTPH7-1:

5'-CCTATTCGTC ATCGCAGACA GCCTTCATCTTCTCGAGATA ACACCTGGAG
CGCGCGTTTC GGTGATGACG-3'

INTPH7-2:

5 5'-AAGTTTCTTT GTCTCCGTCC CACTCAACTTTCTGAGAACA AATGATCCAT
TTTTTGATTA AAATTAAAA AAC-3'

C1-IHXT7:

5'-CCTGCGTGTT CTTCTGAGGTTC-3'

C4-IHXT7:

10 5'-TTTGTAGACG TGGGTCTGCAGGCA-3'

I-KURA31:

5'-CAAAGAATAA ACACAAAAAC AAAAAGTTTTTTTAATTTTA ATCAAAAAAT
GTCCACAAAA TCATATACCAGTAG-3'

I-KURA32:

15 5'-GCACAAATTA GAGCGTGATC ATGAATTAATAAAAGTGTTT GCAAATTAAT
GGGGAGCGCT GATTCTCTTT TG-3'

Integration of the different genes or constructs was
done using homologous recombination. Recombinations
20 were selected on YPglucose (YPD 2% glucose) plates and
then replica plated on to YNB 2% Maltose 5-FOA plates to
select for out-recombination of URA3. To make the
strains prototropic the URA3 was reintroduced by
transformation and homologous recombination.

25

The chimeras or wild-type genes that have been
integrated in the strain constitute the only hexose
transporter.

30 The prototropic strains used in these experiments are
wild type KOY.PK2-1C83, "null mutant" KOY.VW100,
KOY.VWTM6P, KOY.VW101P and KOY.VW102P.

- 39 -

The strains used and generated are summarised in the following table:

	<u>Strain</u>	<u>Genotype</u>	<u>Source</u>
5	KOY.PK2-1C83	MATa MAL2-8c SUC2	Auxotrophic: K-D Entian (Van Dijken et al., 2000, Enzyme Microb. Technol., 26, p706-714
10			Prototrophic: This study
15	KOY.VW100	MATa MAL2-8c SUC2 hxt17ΔA 112ura3-52 gal2Δ::loxP stl1Δ::loxP agt1Δ::loxP ydl247wΔ::loxP yjr160cΔ::loxP hxt13Δ::loxP hxt15Δ::loxP hxt16Δ::loxP hxt14Δ::loxP hxt12Δ::loxP hxt9Δ::loxP hxt11Δ::loxP hxt10Δ::loxP hxt8Δ::loxP hxt514Δ::loxP hxt2Δ::loxP Hxt367Δ::loxP	Auxotrophic: Eckhard Boles (Wieczorke et al., 1999, supra) and this study
20			Prototrophic: This study
25		Integration cassette: (located at the former site of HXT367) strong constitutive promoter from HXT7 the K. lactis URA3 ORF for 5-FOA counter selection and HXT7 terminator.	
30	KOY.TM4	KOY.VW100 with TM4 construct integrated into cassette with subsequent out-recombination of K. lactis URA3 in the cassette.	This study
35		URA3 reintroduced to obtain a prototrophic strain	

- 40 -

5	KOY.TM6P	KOY.VW100 with TM6 construct integrated into cassette with subsequent out-recombination of <i>K. lactis</i> URA3 in the cassette. URA3 reintroduced to obtain a prototropic strain	This study
10	KOY.VW101P	KOY.VW100 HXT1 construct integrated into cassette with subsequent out-recombination of <i>K. lactis</i> URA3 in the cassette. URA3 reintroduced to obtain a prototropic strain	This study
15 20	KOY.VW102P	KOY.VW100 HXT7 construct integrated into cassette with subsequent out-recombination of <i>K. lactis</i> URA3 in the cassette. URA3 reintroduced to obtain a prototropic strain	This study

The protein sequence of TM6 is as follows (Seq. List 1):

```

25  MNSTPDLISP QKSNSNSYE LESGRSKAMN TPEGKNESFH DNLSESQVQP
    AVAPPNTGKG VYVTVSICCV MVAFGGFIFG WDTGTISGFV AQTDFLRRFG
    MKHHDGSHYL SKVRTGLIVS IFNIGCAIGG IVLAKLGDMY GRRIGLIVVV
    VIYTIGIIIQ IASINKWYQY FIGRIISGLG VGGITVLSPM LISEVAPSEM
    RGTLVSCYQV MITLGIFLGY CTNFGTKNYS NSVQWRVPLG LCFAWALFMI
    GGMTFVPESP RYLAEVGKIE EAKRSIAVYN KVAVDDPSVL AEVEAVLAGV
30  EAEKLAGNAS WGELFSSSKTK VLQRLIMGAM IQSLQQLTGD NYFFYYGTTI
    FKAVGLSDSF ETSIVLGIVN FASTFVGIVV VERYGRRTCL LWGAASMTAC
    MVVYASVGVT RLWPNGQDQP SSKGAGNCMI VFACFYIFCF ATTWAPIPYV
    VVSETFPLRV KSKAMSIATA ANWLWGFLIG FFTPFITGAI NFYYGYVFMG
    CLVFMFFYVL LVPVETKGLT LEEVNTMWEE GVLPWKSASW VPPSRRGANY
35  DAEEMTHDDK PLYKRMFSTK

```

At position 279 above, TM6 contains a tyrosine residues

- 41 -

(shown in bold). This represents a modification relative to the naturally occurring sequence in HXT1 in which the residue is serine. As such, modification at this residue or comparable residues in other
 5 transporters forms a further preferred feature of the invention. However, sequences in which position 279 is a serine residue in the above sequence is also included within the scope of this invention.

10 The protein sequence of TM4 is as follows (Seq. list 2):

MNSTPDLISP QKSNSNSYSY LESGRSKAMN TPEGKNESFH DNLSESQVQP
 AVAPPNTGKG VYVTVSICCV MVAFGGFIFG WDTGTISGFV AQTDFLRRFG
 MKHHDGSHYL SKVRTGLIVS IFNIGCAIGG IVLAKLGDMY GRRIGLIVVV
 15 VIYTIGIIIQ IASINKWYQY FIGRIISGLG VGGIAVLSPM LISEVSPKHL
 RGTLVSCYQL MITAGIFLG Y CTNFGTKNYS NSVQWRVPLG LCFAWALFMI
 GGMTFVPESP RYLAEVGKIE EAKRSIAVSN KVAVDDPSVL AEVEAVLAGV
 EAEKLAGNAS WGELFSSKTK VLQRLIMGAM IQSLQQLTGD NYFFYYGTTI
 FKAUGLSDSF ETSIVLGIVN FASTFVGIIYV VERYGRRTCL LWGAASMTAC
 20 MVVYASVGVV RLWPNQDQD SSKGAGNCMI VFACFYIFCF ATTWAPIPYV
 VVSETFPLRV KSKAMSIATA ANWLWGFLIG FFTPFITGAI NFYYGYVFMG
 CLVFMFFYVL LVVPETKGLT LEEVNTMWEE GVLPWKSASW VPPSRRGANY
 DAEEMTHDDK PLYKRMFSTK*

25 Functional constructs which have been identified are TM
 1,2,3,4, 5, 6,10,11,12. These constructs, which form
 preferred aspects of the invention, are made using the
 following portion of HXT1: 1-231 (TM1), 1-391 (TM2), 1-
 449 (TM3), 1-551 (TM4), 1-627 (TM5), 1-741 (TM6), 1-1010
 30 (TM7), 1-1108 (TM8), 1-1214 (TM9), 1-1293 (TM10), 1-1438
 (TM11), 1-1504 (TM12), with the remainder made up of
 HXT7, e.g. 232-1713 in the case of TM1. No
 transformants for TM7,8,9 have yet been identified.

35 *Saccharomyces cerevisiae* KOY.TM6P has been deposited
 under the Budapest treaty on the 20th of June, 2000 at
 the Deutsche Sammlung Mikroorganismen under deposition

- 42 -

number DSM 13555.

Saccharomyces cerevisiae KOY.TM4P has been deposited under the Budapest treaty on the 6 of November, 2000 at the Deutsche Sammlung Mikroorganismen under deposition number DSM 13832.

Growth characterisation

10 Results

Aerobic growth: A diauxic growth behaviour typical for *S. cerevisiae* during aerobic batch cultivation on glucose is shown in Figure 1 and was performed as described previously, ie. in the medium used by Verduyn *et al.* (1992, *supra*) at pH 5.00 in the presence of 5mM glucose, with a starting culture of 0.3 - 0.7 g dry biomass in 1.5l fermentors, stirred at 1500rpm and an air inflow of 0.5 volume of air per vessel volume per minute (vvm). The first phase observed in Figure 1 is due to consumption of glucose with the concomitant production of ethanol and biomass. During the second phase, ethanol serves as the main carbon and energy source. However, during growth of KOY.TM6P a single growth phase is observed (Figure 2). Apparently, the sugar is immediately converted to carbon dioxide and water without any formation of ethanol, i.e. de-repressed conditions are prevalent. During these conditions a generation time of 3.8 h was obtained. This may be calculated from Figure 7 which shows the semi-log plot of biomass versus time. The maximal ethanol concentration was less than 0.12 g/l when using a glucose concentration of 20 g/l. Also other common by-products such as glycerol and acetate were found in negligible amounts. De-repressed conditions was also verified by the fact that on-line measurements of oxygen consumption rate and carbon dioxide formation rate

- 43 -

revealed a respiratory quotient (RQ = carbon dioxide formation rate / oxygen consumption rate) close to 1. Figure 3.

5 KOY.TM4P has also shown growth behaviour very similar to KOY.TM6P (Figure 5). The generation time calculated from the semi-log plot of the optical density versus time has been shown to be 3 to 3.9 h (Figure 6). The maximum ethanol production measured was 0.15 g/l when
10 using 20 g/l of glucose in the medium. As with KOY.TM6P glycerol and acetic acid were found at very low concentrations.

Anaerobic growth: The strain, KOY.TM6P, is able to
15 produce ethanol during anaerobic conditions. It seems, however, that after an initial phase of fairly high activity (as indicated by the specific growth and ethanol production rates) an as yet unidentified factor becomes limiting. This factor can not be such as the
20 essential sterol ergosterol, since supplements that are known to be needed were added to the culture.

Up-take kinetics

Glucose uptake assays has been performed using
25 radiolabelled glucose (Walsh et al., 1994, supra). Cells were grown in a defined medium containing 2% glucose. Cells were harvested at $OD_{610}=1$. Cells were washed and resuspended in 100mM potassium phosphate buffer to a protein concentration of approximately 8-15mg/ml. Cells
30 were incubated with radiolabelled glucose for about 5 sec and the amount of intracellular glucose was determined by liquid scintillation counter.

The *HXT1*-expressing strain (expressing the most abundant
35 low affinity transport protein) showed similar uptake kinetics as the low affinity uptake component in the wild type. Surprisingly, the *HXT7*-expressing strain,

- 44 -

which expresses the most abundant high affinity protein, showed about the same growth behaviour as the wild type and the *HXT1* -expressing strain (data not shown). The only significant difference was that the latter had a much sharper transition during the diauxic phase when the culture shifts from respiro-fermentative to respiratory growth. In other words, the much lower V_{\max} of the uptake system in the *HXT7* strain compared to that of the wild type and the *HXT1* strain does not seem to restrict glucose consumption or the growth rate. It rather seems that the K_m for uptake displayed by the strain is the factor determining a smooth metabolic shift from glucose to another carbon and energy source. However, even lower V_{\max} values, as obtained for the TM strains, seem to limit growth, resulting in diminished growth rates (data not shown).

Table 1. Up-take kinetic data with glucose as substrate.

Strain	K_m (mM)	V_{\max} (nmol/min mg protein)
WT	67±14 ^b	818±93 ^b
(CEN.PK) ^a	1.2±1.2 ^b	80±80 ^b
HXT1	50-100	690
HXT7	2-3	80
TM1	2-3	35
TM4	4-6	80
TM6	7	38
TM12	60	150

^a Literature data (Diderich et al., 2000, in "Animating the cellular map", Stellenbosch University Press, South Africa, IBSN 0-7972-0776-7, p271-275)

^b The higher values refer to the low affinity uptake system and the lower values to the high affinity uptake system.

- 45 -

The results obtained for the various strains described in this Example may be summarized as follows:

5		Wild-type	HXT1	HXT7	TM4	TM6
	Generation time (h)	2	2.5	2.7	3-3.9	3.8
10	Growth yield (biomass/g glucose)	0.3-0.5	0.3-0.35	0.33-0.38	0.34-0.37	0.41
	Glucose consumption (mmol glucose/(g biomass.h))	10	10	<10	2.5	3-4
15	O ₂ consumption rate (mmol O ₂ /(g biomass.h))	2-2.5	3-4	2.2-6.1*	n.d.	3-4.5
20	ethanol production (g/l)	7	6.2	5.2	0.15	0.12

* Reflects continuous increase during the batch culture.
n.d.: not determined

- 46 -

Sequence listing No. 1 (Seq. list 1):

Hexose transporter region of *Saccharomyces cerevisiae*
KOY.TM6P bp 1-741 of HXT1 and bp 742-1713 of HXT7.

5
MNSTPDLISP QKSNSSNSYE LESGRSKAMN TPEGKNESFH DNLSESQVQP
AVAPPNTGKG VYVTVSICCV MVAFGGFIFG WDTGTISGFV AQTDFLRRFG
MKHHDGSHYL SKVRTGLIVS IFNIGCAIGG IVLAKLGDMY GRRIGLIVVV
VIYTIGIIIQ IASINKWYQY FIGRIISGLG VGGITVLSPM LISEVAPSEM
10 RGTLVSCYQV MITLGIFLGY CTNFGTKNYS NSVQWRVPLG LCFAWALFMI
GGMTFVPESP RYLAEVGKIE EAKRSIAVYN KVAVDDPSVL AEVEAVLAGV
EAEKLAGNAS WGELFSSKTK VLQRLIMGAM IQSLQQLTGD NYFFYYGTTI
FKAVGLSDSF ETSIVLGIVN FASTFVGIYV VERYGRRTCL LWGAASMTAC
MVVYASVGVT RLWPNGQDQP SSKGAGNCMI VFACFYIFCF ATTWAPIPYV
15 VVSETFPLRV KSKAMSIATA ANWLWGFLIG FFTPFITGAI NFYYGYVFMG
CLVFMFFYVL LVVPETKGLT LEEVNTMWEE GVLPWKSASW VPPSRRGANY
DAEEMTHDDK PLYKRMFSTK

20 Sequence listing No. 2 (Seq. list 2):

Hexose transporter region of *Saccharomyces cerevisiae*
KOY.TM4P bp 1-551 of HXT1 and bp 552-1713 of HXT7.

25
MNSTPDLISP QKSNSSNSYE LESGRSKAMN TPEGKNESFH DNLSESQVQP
AVAPPNTGKG VYVTVSICCV MVAFGGFIFG WDTGTISGFV AQTDFLRRFG
MKHHDGSHYL SKVRTGLIVS IFNIGCAIGG IVLAKLGDMY GRRIGLIVVV
VIYTIGIIIQ IASINKWYQY FIGRIISGLG VGGIAVLSPM LISEVSPKHL
30 RGTLVSCYQL MITAGIFLGY CTNFGTKNYS NSVQWRVPLG LCFAWALFMI
GGMTFVPESP RYLAEVGKIE EAKRSIAVSN KVAVDDPSVL AEVEAVLAGV
EAEKLAGNAS WGELFSSKTK VLQRLIMGAM IQSLQQLTGD NYFFYYGTTI
FKAVGLSDSF ETSIVLGIVN FASTFVGIYV VERYGRRTCL LWGAASMTAC
MVVYASVGVT RLWPNGQDQP SSKGAGNCMI VFACFYIFCF ATTWAPIPYV
35 VVSETFPLRV KSKAMSIATA ANWLWGFLIG FFTPFITGAI NFYYGYVFMG
CLVFMFFYVL LVVPETKGLT LEEVNTMWEE GVLPWKSASW VPPSRRGANY
DAEEMTHDDK PLYKRMFSTK*

- 47 -

Sequence listing No. 3: TM4 - nucleotide sequence

atgaattcaa ctcccgatct aatatctcct cagaaatcca attcatccaa
ctcatatgaa ttggaatctg gtcgttcaaa ggccatgaat actccagaag
5 gtaaaaatga aagttttcac gacaacttaa gtgaaagtca agtgcaaccc
gccgttgccc ctccaaacac cggaaaaggt gtctacgtaa cggtttctat
ctgttggtgtt atggttgctt tcggtgggtt catatttgga tgggatactg
gtaccatttc tggttttgtt gctcaaactg attttctaag aagatttggt
atgaagcacc acgacggtag tcattacttg tccaagggtga gaactgggtt
10 aattgtctct atttttaaca ttgggtgtgc cattgggtgg atcgtcttag
ccaagctagg tgatgatgtat ggtcgtagaa tcggtttgat tgcgttgta
gtaatctaca ctatcggtat cattattcaa atagcctcga tcaacaagtg
gtaccaatat ttcattggta gaattatctc tggtttaggt gtcggtggta
ttgccgtttt atctcctatg ttgatttctg aagtatcccc aaagcattta
15 aggggtactt tagtctcttg ctaccaattg atgattactg ccggtatttt
cttgggttac tgtaccaact tcggtactaa gaactactcc aactctgtgc
aatggagagt tccattaggt ttgtgttttg cctgggcttt gtttatgatt
gggtggtatga catttggtcc agagtctcca cgttatttggt ctgaagtcgg
taagatcgaa gaagccaaac gttctattgc cgtttctaac aagggtgctg
20 ttgatgatcc atctgttttg gctgaagtcg aagctgtctt ggctgggtga
gaggcagaga aattagctgg taatgcaccc tgggggtgaat tgttttagtag
caagacaaag gtccttcagc gtttgatcat ggggtgctatg attcaatctc
tacaacaatt gacaggtgat aactatttct tctactatgg tactactatt
ttcaaggctg ttggtttgag tgactcttcc gaaacctcta ttgtcttggg
25 tattgttaac tttgcttcca ctttgttggt tatttacggt gttgagagat
atggtcgtcg tacttggttg ctatggggtg ctgcatccat gactgcttgt
atggttgtct atgcttccgt ggggtgcacc agattatggc caaatgggtca
agaccaacca tcttccaagg gtgctggtaa ctgtatgatt gtctttgcct
gtttctatat tttctgtttt gctactacat gggctccaat tccttatgtc
30 gttgtttctg aaactttccc attgagagtc aagtctaagg ctatgtctat
tgctacagct gctaattggg tgtgggggtt cttgattgggt ttcttcactc
catttattac tgggtgctatt aacttctact acggttacgt tttcatgggc
tgtttggtct tcatgttctt ctatgttttg ttagttgttc cagaaactaa
gggtttgact ttggaagaag tcaacaccat gtgggaagaa ggtgttctac
35 catggaagtc tgctcatgg gttccacat ccagaagagg tgccaactac
gacgctgaag aatgactca cgatgacaag ccattgtaca agagaatggt
cagcaccaaa taa

- 48 -

Sequence listing No. 4: TM6 - nucleotide sequence

```

atgaattcaa ctcccgatct aatatctcct cagaaatcca attcatccaa
ctcatatgaa ttggaatctg gtcgttcaaa ggccatgaat actccagaag
5 gtaaaaatga aagttttcac gacaacttaa gtgaaagtca agtgcaaccc
gccgttgccc ctccaaacac cggaaaagggt gtctacgtaa cggtttctat
ctgttggtgtt atgggttgctt tccgttggttt catatttgga tgggatactg
gtaccatttc tgggttttggt gctcaaactg attttctaag aagatttggt
atgaagcacc acgacggtag tcattacttg tccaagggtga gaactggttt
10 aattgtctct atttttaaca ttggttggtgc cattgggtgg atcgtcttag
ccaagctagg tgatatgtat ggtcgtagaa tcggtttgat tgcgttgta
gtaatctaca ctatcggtat cattattcaa atagcctcga tcaacaagtg
gtaccaatat ttcattggta gaattatctc tggtttaggt gtcgggtgta
tcacagtttt atctcccatg ctaatatctg aggtcgcccc cagtgaatg
15 agaggcacct tggtttcatg ttaccaagtc atgattactt taggtatttt
cttaggttac tgtaccaatt ttggtaccaaa gaattactca aactctgtcc
aatggagagt tccattagggt ttgtgtttcg cctgggcctt atttatgatt
ggtggtatga catttggtcc agagtctcca cgttattttg ctgaagtcgg
taagatcgaa gaagccaaac gttctattgc cgtttataac aaggttgctg
20 ttgatgatcc atctgttttg gctgaagtcg aagctgtctt ggctggtgta
gaggcagaga aattagctgg taatgcatcc tgggggtgaat tgtttagtag
caagacaaag gtccttcagc gtttgatcat gggtgctatg attcaatctc
tacaacaatt gacaggtgat aactatttct tctactatgg tactactatt
ttcaaggctg ttggtttgag tgactcttcc gaaacctcta ttgtcttggg
25 tattgttaac tttgcttcca cctttgttgg tatttacgtt gttgagagat
atgggtcgctg tacttggttg ctatggggtg ctgcatccat gactgcttgt
atggttggtc atgcttccgt ggggtgtcacc agattatggc caaatggtca
agaccaacca tcttccaagg gtgctggtaa ctgtatgatt gtctttgcct
gtttctatat tttctgtttt gctactacat gggctccaat tccttatgtc
30 gttgtttctg aaactttccc attgagagtc aagtctaagg ctatgtctat
tgctacagct gctaattgggt tgtgggggtt cttgattgggt ttcttcactc
catttattac tgggtgctatt aacttctact acggttacgt tttcatgggc
tgtttggtct tcatgttctt ctatgttttg ttagttgttc cagaaactaa
gggtttgact ttggaagaag tcaacaccat gtgggaagaa ggtgttctac
35 catggaagtc tgcctcatgg gttccaccat ccagaagagg tgccaactac
gacgctgaag aatgactca cgatgacaag ccattgtaca agagaatgtt
cagcaccaaa taa

```

- 49 -

Sequence listing No. 5 (Seq. list 5): Expression
cassette sequence - nucleotide sequence

tctcgttagga acaatttcgg gcccctgcgt gttcttctga ggttcattctt
5 ttacattttgc ttctgctgga taattttcag aggcaacaag gaaaaattag
atggcaaaaa gtcgtctttc aaggaaaaat cccaccatc tttcgagatc
ccctgtaact tattggcaac tgaaagaatg aaaaggagga aaatacaaaa
tatactagaa ctgaaaaaaa aaaagtataa atagagacga tatatgccaa
tacttcacaa tgttcgaatc tattcttcat ttgcagctat tgtaaaataa
10 taaaacatca agaacaaaca agctcaactt gtcttttcta agaacaaaga
ataaacacaa aaacaaaaag tttttttaat tttaatcaaa aaatgtccac
aaaatcatat accagtagag ctgagactca tgcaagtccg gttgcatcga
aacttttacg tttaatggat gaaaagaaga ccaatttggt tgcttctctt
gacgttcggt cgactgatga gctattgaaa cttgttgaaa cgttgggtcc
15 atacattttgc cttttgaaaa cacacgttga tatcttggtat gatttcagtt
atgaggggtac tgcgtttcca ttgaaagcat tggcagagaa atacaagttc
ttgatattttg aggacagaaa attcgccgat atcggtaca cagtcaaatt
acaatataca tcgggcgttt accgtatcgc agaattggtct gatatcacca
acgcccacgg ggttactggt gctggtattg ttgctggctt gaaacaaggt
20 gcgcaagagg tcaccaaaga accaagggga ttattgatgc ttgctgaatt
gtcttccaag ggttctctag cacacggtga atatactaag ggtaccgttg
atattgcaaa gagtataaa gatttcgtta ttgggttcat tgctcagaac
gatatgggag gaagagaaga agggtttgat tggctaataca tgacccacgg
tgtaggttta gacgacaaag gcgatgcatt gggtcagcag tacagaaccg
25 tcgacgaagt tgtaagtggg ggatcagata tcatcattgt tggcagagga
cttttcgcca agggtagaga tcctaagggt gaaggtgaaa gatacagaaa
tgctggatgg gaagcgtacc aaaagagaat cagcgtccc cattaatttg
cgaacacttt tattaattca tgatcacgct ctaatttggt catttgaaat
gtactctaata tctaatttta tatttttaat gatattctga aaagtaaata
30 cgtttttaat atatacaaaa taatacagtt taattttcaa gtttttgatc
atttgttctc agaaagttga gtgggacgga gacaaagaaa ctttaaagag
aaatgcaaag tgggaagaag tcagttgttt accgaccgca ctgttattca
caaatattcc aattttgcct gcagaccac gtctacaaat tttgggttagt
ttggtaaatg gtaaggatat agtagagcct ttttgaaatg ggaaatatct
35 tctttttctg tatcccgctt caaaaagtgt ctaatgagtc agttatttct
ttcttactca tcgcccgtca cttaaaagaa gaaaaattac tttcatgatg
cgaagcgaaa aaaattttta gcttcaattt tcacaatgca tct

- 50 -

Claims:

1. A modified *Saccharomyces* yeast which produces lower levels of ethanol than wild-type yeast under aerobic
5 conditions and saccharide concentrations of 5mM or more, preferably 2% glucose, and which exhibits a growth rate of at least 30% of the wild-type yeast.
2. A yeast as claimed in claim 1 wherein said yeast
10 produces less than 0.25g/l, preferably less than 0.12g/l ethanol.
3. A yeast as claimed in claim 1 or 2 wherein said
15 yeast exhibits a growth rate of at least 50%, preferably at least 70% of the wild-type yeast.
4. A yeast as claimed in any one of claims 1 to 3 wherein said yeast is a *Saccharomyces cerevisiae*.
- 20 5. A yeast as claimed in any one of claims 1 to 4 wherein said yeast contains a chimeric nucleotide sequence (a chimeric construct) which is stably transformed into the genetic material of the yeast, wherein the construct comprises at least a first
25 sequence from the nucleotide sequence encoding a first saccharide transporter or a sequence related to or derived therefrom and a second sequence from the nucleotide sequence encoding a different second
30 saccharide transporter or a sequence related to or derived therefrom, wherein said saccharide is preferably glucose.

- 51 -

6. A yeast as claimed in 5 wherein said chimeric construct comprises a sequence having the form

A - B

5

wherein

A is said first sequence comprising nucleotide bases w to x;

10 B is said second sequence comprising nucleotide bases (x+y) to z;

wherein A and B are derived from the nucleotide sequences of said different saccharide transporters or from sequences related to or derived therefrom;

15 w is a first position within the nucleotide sequence from which said first sequence is derived, which is less than x, preferably 1 to 50;

20 x is a second position within the nucleotide sequence from which said first sequence is derived and is greater than w and is preferably a number from 500 to 850;

y is an integer, preferably less than 3;

x+y is a first position within the nucleotide sequence from which said second sequence is derived;

25 and z is a second position within the nucleotide sequence from which said second sequence is derived and is greater than x+y, preferably from 1600 to 1713; wherein said values refer to the position within the nucleotide sequence of said saccharide transporter, e.g. HXT1 or HXT7 or a comparable sequence thereof.

30

7. A yeast as claimed in claim 5 or 6 wherein said first saccharide transporter is a high affinity saccharide transporter of the yeast *Saccharomyces* and said second saccharide transporter is a low affinity

35 saccharide transporter of the yeast *Saccharomyces*.

8. A yeast as claimed in any one of claims 5 to 7

- 52 -

wherein said transporters are selected from the list consisting of: HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably from *Saccharomyces cerevisiae*, or sequences related to or derived from the sequences thereof.

9. A yeast as claimed in any one of claims 5 to 8 wherein the chimeric construct comprises one or more sequences or portions thereof of the sequences encoding any one of HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably from *Saccharomyces cerevisiae*,
or a sequence which hybridizes to said sequence or portion thereof under non-stringent binding conditions of 6 x SSC/50% formamide at room temperature and washing under conditions of high stringency, e.g. 2 x SSC, 65°C, where SSC = 0.15 M NaCl, 0.015M sodium citrate, pH 7.2,
or a sequence which exhibits at least 95% sequence identity to said sequence or portion thereof,
or a sequence complementary to any of the aforesaid sequences,
which sequence or portion thereof may comprise a first or second sequence as defined in any one of claims 5 to 8.

10. A yeast as claimed in any one of claims 5 to 8 wherein the chimeric construct comprises a sequence which encodes an amino acid sequence which comprises one or more sequences or portions thereof of the sequences of any one of HXT1 to HXT17, GAL2, SNF3, RGT2, AGT1, YDL247w and YJR160c, preferably from *Saccharomyces cerevisiae*,
or a sequence which exhibits at least 95% sequence identity to said sequence or portion thereof,
which sequence or portion thereof is encoded by a nucleotide sequence which may comprise a first or second

- 53 -

sequence as defined in any one of claims 5 to 8.

11. A yeast as claimed in any one of claims 7 to 10
wherein said low affinity transporter is HXT1 or 3 and
5 said high affinity transporter is HXT2, 4, 6, 7 or
GAL2P.

12. A yeast as claimed in any one of claims 5 to 11
wherein said construct comprises sequences from, or
10 related to or derived from HXT 1 and HXT7.

13. A yeast as claimed in any one of claims 6 to 12
wherein x is a position in the nucleotide sequence
encompassed by the third to ninth transmembrane
15 stretches of HXT1 or HXT7 or a comparable sequence,
preferably x = 525-575 and/or 720-770.

14. A yeast as claimed in any one of claims 6 to 13
wherein x = 551 or 741, w and y = 1 and z = 1713.

20 15. A yeast as claimed in any one of claims 5 to 14
wherein said chimeric construct encodes a chimeric
polypeptide having a total of 10 to 14 transmembrane
domains.

25 16. A yeast as claimed in any one of claims 5 to 15
wherein said chimeric construct contains 2 or more
sequences from the nucleotide sequence of at least one
transporter molecule or a sequence related to or derived
30 therefrom or contains sequences from the nucleotide
sequences of more than 2 transporters or the sequences
related to or derived therefrom.

35 17. A yeast as claimed in any one of claims 5 to 16
wherein the yeast cell into which said chimeric
construct is introduced is a null strain without
saccharide transporting properties.

- 54 -

18. A yeast as claimed in any one of claims 5 to 17 wherein said chimeric construct comprises the nucleotide sequence encoding Sequence ID Nos. 1 or 2 or comprises the nucleotide sequence of Sequences ID Nos. 3 or 4 or a functional equivalent of said sequences.
19. A yeast as claimed in claim 18 denoted *Saccharomyces cerevisiae* KOY.TM4P or KOY.TM6P having the deposition number DSM (Deutsche Sammlung Mikroorganismen) 13832 or DSM 13555, respectively or a functional equivalent thereof.
20. A nucleic acid molecule comprising a chimeric nucleotide sequence as defined in any one of claims 5 to 19 or a complementary sequence thereto.
21. A vector or host cell comprising a nucleic acid molecule as defined in claim 20.
22. A polypeptide comprising a sequence encoded by a nucleic acid molecule as defined in claim 20 or a functionally equivalent protein thereof.
23. A method of inserting exogenous genetic material into a yeast cell as defined in any one of claims 1 to 19 to provide a yeast cell which produces a product, said method comprising at least the steps of introducing said material, preferably contained within a vector, into said cell, wherein said exogenous material encodes said product or portion thereof or encodes a polypeptide or part thereof which facilitates the direct or indirect production of said product or portion thereof, or which affects the expression of said polypeptide or product.
24. A method as claimed in claim 23 wherein said product is a high or low molecular metabolite, a bulk or fine chemical, a food stuff, a functional food or a

- 55 -

therapeutic agent.

25. A method as claimed in claim 25 wherein said
product is an amino acid, a peptide, a polypeptide, a
5 sugar, a small polyol or CO₂.

26. A yeast cell obtainable by the method of any one of
claims 23 to 25.



10 27. A method of preparing a product, comprising growing
yeast cells as defined in any one of claims 1 to 19 or
26 under aerobic conditions in the presence of high
saccharide, preferably glucose, concentrations.

15 28. A method as claimed in claim 27, additionally
comprising the step of isolating the product thus
formed.



29. A product obtained by the method of claim 28.

20 30. A method or product as claimed in any one of claims
27 to 29 wherein said product is a low alcohol or non-
alcoholic beverage.



1 / 4

Figure 1Figure 2

2 / 4

Figure 3Figure 4

3 / 4

Figure 5Figure 6

4 / 4

TM6; 2%Glucose;Aerobic




Figure 7A

TM4; 2% Glucose, Aerobic




Figure 7B

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 01/03079

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C12N1/19 C12N15/62 C12P1/02 C07K14/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, CHEM ABS Data, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 14258 A (NOVONORDISK AS) 16 March 2000 (2000-03-16) the whole document	1-3, 23-29
A	SHERWOOD PETER W ET AL: "A glucose transporter chimera confers a dominant negative glucose starvation phenotype in <i>Saccharomyces cerevisiae</i> ." GENETICS, vol. 155, no. 2, June 2000 (2000-06), pages 989-992, XP001031164 ISSN: 0016-6731 the whole document	
A	EP 0 785 275 A (GIST BROCADES BV) 23 July 1997 (1997-07-23) the whole document	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

14 November 2001

Date of mailing of the international search report

28/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lejeune, R

INTERNATIONAL SEARCH REPORT

Int tional Application No
PCT/GB 01/03079

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

A	<p>BROWN CELESTE J ET AL: "Multiple duplications of yeast hexose transport genes in response to selection in a glucose-limited environment." MOLECULAR BIOLOGY AND EVOLUTION, vol. 15, no. 8, August 1998 (1998-08), pages 931-942, XP001031140 ISSN: 0737-4038 the whole document</p>	
---	--	--

A	<p>NISHIZAWA KAZUHISA ET AL: "Substrate recognition domain of the Gal2 galactose transporter in yeast Saccharomyces cerevisiae as revealed by chimeric galactose-glucose transporters." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 6, 1995, pages 2423-2426, XP002182850 ISSN: 0021-9258 the whole document</p>	
---	---	--

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03079

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0014258	A	16-03-2000	AU 5504099 A	27-03-2000
			WO 0014258 A1	16-03-2000
			EP 1109922 A1	27-06-2001
			US 6190883 B1	20-02-2001
EP 0785275	A	23-07-1997	EP 0785275 A2	23-07-1997
			GR 3034466 T3	29-12-2000
			AT 194654 T	15-07-2000
			AU 711355 B2	14-10-1999
			AU 1017097 A	24-07-1997
			CA 2195124 A1	17-07-1997
			DE 69702457 D1	17-08-2000
			DE 69702457 T2	23-11-2000
			DK 785275 T3	06-11-2000
			ES 2150185 T3	16-11-2000
			JP 9220091 A	26-08-1997
			PT 785275 T	29-12-2000
			US 6159725 A	12-12-2000
			ZA 9700358 A	17-07-1997

THIS PAGE BLANK (USPTO)